Literature DB >> 16849473

Genetic dissection of the effects of stimulatory and inhibitory IgG Fc receptors on murine lupus.

Qingshun Lin1, Yan Xiu, Yi Jiang, Hiromichi Tsurui, Kazuhiro Nakamura, Sanki Kodera, Mareki Ohtsuji, Naomi Ohtsuji, Wakana Shiroiwa, Kazuyuki Tsukamoto, Hirofumi Amano, Eri Amano, Katsuyuki Kinoshita, Katsuko Sudo, Hiroyuki Nishimura, Shozo Izui, Toshikazu Shirai, Sachiko Hirose.   

Abstract

Immune complex (IC)-mediated tissue inflammation is controlled by stimulatory and inhibitory IgG Fc receptors (FcgammaRs). Systemic lupus erythematosus is a prototype of IC-mediated autoimmune disease; thus, imbalance of these two types of FcgammaRs is probably involved in pathogenesis. However, how and to what extent each FcgammaR contributes to the disease remains unclear. In lupus-prone BXSB mice, while stimulatory FcgammaRs are intact, inhibitory FcgammaRIIB expression is impaired because of promoter region polymorphism. To dissect roles of stimulatory and inhibitory FcgammaRs, we established two gene-manipulated BXSB strains: one deficient in stimulatory FcgammaRs (BXSB.gamma(-/-)) and the other carrying wild-type Fcgr2b (BXSB.IIB(B6/B6)). The disease features were markedly suppressed in both mutant strains. Despite intact renal function, however, BXSB.gamma(-/-) had IC deposition in glomeruli associated with high-serum IgG anti-DNA Ab levels, in contrast to BXSB.IIB(B6/B6), which showed intact renal pathology and anti-DNA levels. Lymphocytes in BXSB.gamma(-/-) were activated, as in wild-type BXSB, but not in BXSB.IIB(B6/B6). Our results strongly suggest that both types of FcgammaRs in BXSB mice are differently involved in the process of disease progression, in which, while stimulatory FcgammaRs play roles in effecter phase of IC-mediated tissue inflammation, the BXSB-type impaired FcgammaRIIB promotes spontaneous activation of self-reactive lymphocytes and associated production of large amounts of autoantibodies and ICs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16849473     DOI: 10.4049/jimmunol.177.3.1646

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

Review 1.  Significance of MHC class II haplotypes and IgG Fc receptors in SLE.

Authors:  Sachiko Hirose; Yi Jiang; Hiroyuki Nishimura; Toshikazu Shirai
Journal:  Springer Semin Immunopathol       Date:  2006-09-14

2.  Defining the immunological phenotype of Fc receptor-like B (FCRLB) deficient mice: Confounding role of the inhibitory FcγRIIb.

Authors:  Keiji Masuda; Hiromi Mori; Osamu Ohara; Manabu Nakayama; Ji-Yang Wang; Peter D Burrows
Journal:  Cell Immunol       Date:  2010       Impact factor: 4.868

3.  In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner.

Authors:  Heike Albert; Mattias Collin; Diana Dudziak; Jeffrey V Ravetch; Falk Nimmerjahn
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-24       Impact factor: 11.205

4.  Genomic pathology of SLE-associated copy-number variation at the FCGR2C/FCGR3B/FCGR2B locus.

Authors:  Michael Mueller; Paula Barros; Abigail S Witherden; Amy L Roberts; Zhou Zhang; Helmut Schaschl; Chack-Yung Yu; Matthew E Hurles; Catherine Schaffner; R Andres Floto; Laurence Game; Karyn Meltz Steinberg; Richard K Wilson; Tina A Graves; Evan E Eichler; H Terence Cook; Timothy J Vyse; Timothy J Aitman
Journal:  Am J Hum Genet       Date:  2012-12-20       Impact factor: 11.025

5.  Analysis of a wild mouse promoter variant reveals a novel role for FcγRIIb in the control of the germinal center and autoimmunity.

Authors:  Marion Espéli; Menna R Clatworthy; Susanne Bökers; Kate E Lawlor; Antony J Cutler; Frank Köntgen; Paul A Lyons; Kenneth G C Smith
Journal:  J Exp Med       Date:  2012-10-29       Impact factor: 14.307

6.  Increased expression of FcgammaRI/CD64 on circulating monocytes parallels ongoing inflammation and nephritis in lupus.

Authors:  Yi Li; Pui Y Lee; Eric S Sobel; Sonali Narain; Minoru Satoh; Mark S Segal; Westley H Reeves; Hanno B Richards
Journal:  Arthritis Res Ther       Date:  2009-01-14       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.